PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: Assignment of Security Interest

CONVEYING PARTY DATA

Name: Drug Royalty USA, Inc.
Execution Date: 03/21/2005

RECEIVING PARTY DATA

Name: Drug Royalty LLC
Street Address: 919 N. Market Street
Internal Address: Suite 770
City: Wilmington
State/Country: DELAWARE
Postal Code: 19801

PROPERTY NUMBERS Total: 4

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent Number</td>
<td>4874794</td>
</tr>
<tr>
<td>Patent Number</td>
<td>5071879</td>
</tr>
<tr>
<td>Patent Number</td>
<td>5534554</td>
</tr>
<tr>
<td>Patent Number</td>
<td>5952392</td>
</tr>
</tbody>
</table>

CORRESPONDENCE DATA

Fax Number: (212)697-1559

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 2126966000
Email: patent@cm-p.com
Correspondent Name: Michael J. Brown /Curtis, Mallet-Prevost
Address Line 1: 101 Park Avenue
Address Line 2: 34th Floor
Address Line 4: New York, NEW YORK 101780061

NAME OF SUBMITTER: Michael J. Brown

Total Attachments: 3
ASSIGNMENT OF SECURITY INTEREST IN PATENTS

WHEREAS, Drug Royalty USA, Inc., a Nevada corporation ("Assignor"), is the assignee of a security interest in certain patents owned by Avanir Pharmaceuticals. said security interest recorded with the U.S. Patent and Trademark Office against said patents at Reel 013608 and Frame 0920 and identified on the attached Schedule A (the "Security Interest"); and whereas, Assignor is the sole owner of the Security Interest, and,

WHEREAS, Drug Royalty LLC, a Delaware limited liability company located at 919 N. Market Street, Suite 770 Wilmington DE 19801, ("Assignee") is desirous of acquiring the entire right, title and interest in the Security Interest;

NOW THEREFORE, in consideration of the sum of ten dollars ($10.00) and other good and valuable consideration, the receipt whereof is acknowledged, Assignor, by these presents does sell, assign and transfer unto Assignee the full and exclusive right, title and interest in and to the Security Interest.

This assignment is effective as of March 21, 2005.

[Signature Page Follows]
DRUG ROYALTY USA, INC.

Dated: March ____, 2005

By: ________________________________
   Name: Behzad Khosrowshahi
   Title: President

DRUG ROYALTY LLC

Dated: March ____, 2005

By: ________________________________
   Name: Behzad Khosrowshahi
   Title: President
Schedule A

Security Interest granted by Avanir Pharmaceuticals to Drug Royalty USA, Inc., executed on December 24, 2002 and recorded with the U.S. Patent and Trademark Office on December 26, 2002, as applied to the following patents:

<table>
<thead>
<tr>
<th>Patent No.</th>
<th>Issue Date</th>
<th>Serial No.</th>
<th>Filing Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4874794</td>
<td>10/17/1989</td>
<td>07345084</td>
<td>04/28/1989</td>
<td>Inflammatory Disease Treatment</td>
</tr>
<tr>
<td>5071879</td>
<td>12/10/1991</td>
<td>07431304</td>
<td>11/02/1989</td>
<td>Systemic Antiviral Treatment</td>
</tr>
<tr>
<td>5534554</td>
<td>07/09/1996</td>
<td>08299944</td>
<td>09/02/1994</td>
<td>Sucrose Ester-C20 to C28 Alcohol Formulations</td>
</tr>
<tr>
<td>5952392</td>
<td>09/14/1999</td>
<td>08916624</td>
<td>08/22/1997</td>
<td>Long-Chain Alcohols, Alkanes, Fatty Acids and Amides in the Treatment of Burns and Viral Inhibition</td>
</tr>
</tbody>
</table>